Industry reports
Editor highlights

Publication dates

data types

Biogen Idec Market and Forecasts, April 2014

You might be interested in: clinical trial, biosimilar, drug, more »


 

» View Public Reports

1-10 of 54 reports for Biogen Idec

Pharmaceutical in The United States : Innovation and Technology Trends

  • Industry report
  • June 2012
  • 191 pages
  • by Market Research Publisher

... Pierce, biogen idec S svp, global medical affairs since march 2012, joined biogen idec's hemophilia therapeutic area as a vice president and chief medical office in 2009. Prior to joining biogen idec, dr ...

U.S. Drug Discovery Market : Innovation and Technology Trends

  • Industry report
  • October 2012
  • 18 pages

... Multiple sclerosis (elan / biogen idec) Actemra which is used to treat rheumatoid arthritis (chugai / roche) 2 antibodies (originating from mrc labs) have been successfully humanized, re- vald ...

U.S. Biopharmaceutical Business Brief

  • Industry report
  • January 2012
  • 2 pages

... Biopharmaceutical manufacturing, By j rg th mmes (vice president of global engineering and facilities at biogen idec) Improving access and affordability to biopharmaceuticals in the emerging markets through ...

E-commerce in The United States and Lebanon : Innovation and Technology Trends

  • Industry report
  • January 2012
  • 16 pages

... Mascoma corp. And glycofi/merck (lebanon, nh). Postdoc, ucsd and stanford. Advisors rainer fuchs cio, harvard medical school; previously vp r&d information technology, biogen idec and exec. Dir ...

Pharmaceutical Business in The United States and Canada

  • Industry report
  • June 2012
  • 22 pages

... Biosciences Abcam Agilent technologies Amgen biogen idec Bristol-myers squibb Cephalon Celgene corporation Cellectis Cerus Covance biomarker center of excellence Cyprotex ...

Psoriasis Therapeutics Business Brief

  • Industry report
  • January 2013
  • 8 pages

... Laboratories 19 3.5 Fumaderm (dimethyl fumarate and ethyl fumarate) - biogen idec 20 3.6 Humira (adalimumab) - abbvie inc. 21 3.7 Enbrel (etanercept) - amgen inc. 22 3.8 Remicade (infliximab) - janssen ...

Infectious Disease Market in Poland and The United States

  • Industry report
  • September 2013
  • 24 pages

... With copaxone trimesta opportunity oral add-on ms therapy 8 nyse mkt: syn teva/copaxone $4.178 30% biogen idec/avonex $2.929 21% Merck kgaa/rebif $2.425 17% biogen idec/tysabri $1.703 12 ...

Biotechnology in The United Kingdom and China : Innovation and Technology Trends

  • Industry report
  • January 2012
  • 24 pages

... Eisai monoclonal antibody 5.6 10.1 2 Avastin roche monoclonal antibody 5.7 8.9 3 Enbrel amgen/pfizer/takeda recombinant product 6.5 7.3 4 Rituxan roche/biogen idec monoclonal antibody 5.6 6.8 5 Crestor astra ...

U.S. Education and Training Business Brief

  • Industry report
  • January 2013
  • 33 pages

... And nanotechnology at uncg, the david h. Murdock research institute (dhmri), commercialization at wake forest innovation, biogen idec, targacept, patheon (formerly, banner pharma), transtech pharma, and tengion ...

U.S. Drug Sector

  • Industry report
  • August 2013
  • 32 pages

... With parexel to bring 5 biosimilar products biogen idec, samsung and merck have a joint venture sandoz has five products in phase iii filgrastim, pegfilgrastim, epo, etanercept for psoriasis, rituximab ...

» Purchase Premium Reports (From $ 125 - $ 11 400)

About 400 reports for Biogen Idec
Personalized Medicine Partnering Terms and Agreements

Personalized Medicine Partnering Terms and Agreements

  • $ 3 295
  • Industry report
  • April 2014
  • by Currentpartnering

Comprehensive understanding and unprecedented access to the personalized medicine partnering deals and agreements entered into by the worlds leading healthcare companies. The Personalized Medicine Partnering ...


» Read our Company Profiles

1 Companies for Biogen Idec

Roche Holding AG

Switzerland

ReportLinker is a professional search engine that provides an easy access to 1,2 million market research reports and industry statistics published by 200,000 authoritative sources.